<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597918</url>
  </required_header>
  <id_info>
    <org_study_id>MR41926</org_study_id>
    <secondary_id>2020-001174-30</secondary_id>
    <nct_id>NCT04597918</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab</brief_title>
  <acronym>ALTIMETER</acronym>
  <official_title>An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, prospective, multicenter, open-label, single-arm, interventional,&#xD;
      Phase IIb study designed to explore the associations over time between clinical assessments,&#xD;
      multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic&#xD;
      polymorphisms in participants with diabetic macular edema (DME) who are treated with&#xD;
      faricimab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) at Day 112</measure>
    <time_frame>Baseline, Day 112</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Faricimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faricimab</intervention_name>
    <description>A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).</description>
    <arm_group_label>Faricimab</arm_group_label>
    <other_name>RO6867461</other_name>
    <other_name>RG7716</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus (Type 1 or Type 2), as defined by the World Health&#xD;
             Organization (WHO) and/or American Diabetes Association&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) ≤10%&#xD;
&#xD;
          -  Patients who are intravitreal (IVT) treatment-naïve in the study eye&#xD;
&#xD;
          -  Diabetic macular edema (DME) defined as macular thickening by spectral-domain optical&#xD;
             coherence tomography (SD-OCT) involving the center of the macula. This inclusion&#xD;
             criterion is to be assessed by the central reading center (CRC).&#xD;
&#xD;
          -  Decreased visual acuity (VA) attributable primarily to DME&#xD;
&#xD;
          -  Clear ocular media and adequate pupillary dilation to allow acquisition of good&#xD;
             quality retinal images to confirm diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently untreated diabetes mellitus or previously untreated patients who initiated&#xD;
             oral or injectable anti-diabetic medication within 3 months prior to Day 1&#xD;
&#xD;
          -  Any known hypersensitivity to any of the components in the faricimab injection,&#xD;
             dilating eye drops, or any of the anesthetics and antimicrobial preparations used by&#xD;
             the patient during the study&#xD;
&#xD;
          -  Any major illness or major surgical procedure within 1 month before the Day 1. One&#xD;
             re-screening for this criterion is permitted&#xD;
&#xD;
          -  History of other diseases, other non-diabetic metabolic dysfunction, physical&#xD;
             examination finding, historical or current clinical laboratory finding giving&#xD;
             reasonable suspicion of a condition that contraindicates the use of the faricimab or&#xD;
             that might affect interpretation of the results of the study or renders the patient at&#xD;
             high-risk for treatment complications, in the opinion of the Investigator&#xD;
&#xD;
          -  Active cancer within the past 12 months prior to Day 1 except for appropriately&#xD;
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate&#xD;
             cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for &gt;12&#xD;
             months&#xD;
&#xD;
          -  Stroke or myocardial infarction within 12 months prior to the Day 1. One re-screening&#xD;
             for this criterion is permitted&#xD;
&#xD;
          -  Any febrile illness within 1 week prior to Day 1. One re-screening for this criterion&#xD;
             is permitted&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the final dose of faricimab&#xD;
&#xD;
          -  Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within&#xD;
             6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis&#xD;
             at any time during the study&#xD;
&#xD;
          -  Any condition resulting in a compromised immune system that is likely to impact the&#xD;
             aqueous humor (AH) inflammatory biomarkers.&#xD;
&#xD;
          -  Patients who are currently enrolled in or have participated in any other clinical&#xD;
             study involving an investigational product or device, or in any other type of medical&#xD;
             research, within 3 months or 5 half-lives prior to Day 1 and up to completion of the&#xD;
             current study&#xD;
&#xD;
          -  Substance abuse occurring within 12 months prior to screening, in the Investigator's&#xD;
             judgment&#xD;
&#xD;
          -  Use of systemic immunomodulatory treatments within 6 months or 5 half-lives prior to&#xD;
             Day 1, systemic corticosteroids within 1 month prior to Day 1&#xD;
&#xD;
          -  Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Use of systemic medications known to be toxic to the lens, retina or optic nerve used&#xD;
             during the 6-month period or 5 half-lives prior to Day 1 or likely need to be used&#xD;
&#xD;
          -  Received a blood transfusion within 3 months prior to the screening visit, received&#xD;
             any treatment that leads to immunosuppression within 6 months or 5 half-lives prior to&#xD;
             Day 1&#xD;
&#xD;
        Ocular Exclusion Criteria for Study Eye:&#xD;
&#xD;
          -  High-risk PDR. This exclusion criterion is to be assessed by the CRC&#xD;
&#xD;
          -  Any history of or ongoing rubeosis iridis&#xD;
&#xD;
          -  Any panretinal photocoagulation or macular laser photocoagulation treatment received&#xD;
             in the study eye prior to the screening visit or expected to be received between the&#xD;
             screening visit and Day 1&#xD;
&#xD;
          -  Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in&#xD;
             the study eye and no such treatment planned for the time between screening and Day 1&#xD;
&#xD;
          -  Any treatment for dry eye disease in the last month prior to Day 1. Lubricating eye&#xD;
             drops and ointments are permitted&#xD;
&#xD;
          -  Any treatment with anti-inflammatory eye drops within 1 month prior to Day 1&#xD;
&#xD;
          -  Any intraocular surgery within 3 months prior to Day 1 or any planned surgery during&#xD;
             the study, any glaucoma surgery prior to the screening visit&#xD;
&#xD;
          -  History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Any active or suspected ocular or periocular infections on Day 1&#xD;
&#xD;
          -  Any presence of active intraocular inflammation on Day 1 or any history of intraocular&#xD;
             inflammation&#xD;
&#xD;
          -  Any history of idiopathic, infectious, or noninfectious uveitis&#xD;
&#xD;
          -  Any current or history of ocular disease other than DME that may confound assessment&#xD;
             of the macula or affect central vision&#xD;
&#xD;
          -  Any current ocular condition or other causes of visual impairment for which, in the&#xD;
             opinion of the Investigator, VA loss would not improve from resolution of macular&#xD;
             edema&#xD;
&#xD;
        Ocular Exclusion Criteria for Fellow Eye:&#xD;
&#xD;
          -  Patient is currently receiving treatment with brolucizumab or bevacizumab in the&#xD;
             non-study eye and is unwilling to switch to a protocol allowed non-study eye treatment&#xD;
             during the study&#xD;
&#xD;
          -  Any previous treatment with Iluvien® or Retisert® in the non-study eye&#xD;
&#xD;
          -  Non-functioning non-study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MR41926 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Group/Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates, PC</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, MD PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina PC</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Is. Vitreoretinal Consult</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Res Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Research Center for Retina</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Strategic Clinical Research Group, LLC</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oftalmológico Dr. Charles S.A.</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1116</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oftalmos</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1120AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Specialists of Toronto</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Retina Centre of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2B 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Augenheilkunde</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe; U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale San Raffaele;U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia Ospedale S. Maria Della Misericordia; Clinica Oculistica</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucestershire</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

